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Unparalleled Contribution of Technetium-99m
to Medicine Over 5 Decades
William C. Eckelman, PHD
Bethesda, MarylandSince the first tracer study by George C. de
Hevesy in 1923, in which he used the tracer
principle to study the absorption and translo-
cation of lead nitrate with Pb-212 (1), radio-
nuclides have been used both in vitro and in
vivo to trace various biologic processes. The
radioisotopes of iodine in particular have
played an important role in the early develop-
ment of nuclear medicine since their use in
thyroid metabolism studies (I-131) and radio-
immunoassay (I-125). Although I-131 did
not have ideal nuclear properties for external
imaging with the Anger camera, it was used
extensively because of its ready availability
and easy conversion to the appropriate chem-
ical form. A long list of I-131–labeled radio-
tracers illustrates its importance in the post-
war period (2). However, the rapid succession
of discoveries of the element technetium (Tc),
the molybdenum-99 (Mo-99)/Tc-99m gener-
ator (Fig. 1) and the “instant” kit (Fig. 2)
concept led to unparalleled growth in nuclear
medicine (3). Tc-99m radiopharmaceutical
imaging is a key diagnostic in 85% of
nuclear medicine procedures. There are
about 40 million procedures performed
worldwide per year, which includes 20 mil-
lion procedures in North America.
The early history of technetium and tech-
netium radiopharmaceuticals is best charac-
terized by the quote from Louis Pasteur: “In
the fields of observation, chance favors only
the prepared mind” (4). In the mid-1930s,
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ing element to the right of Mo and above
rhenium. During a visit to the Radiation
Laboratory at the University of California,
Berkeley, California, Emilio Segre obtained
metal pieces of a cyclotron deflector, which
was made of Mo, and on his return to Italy
investigated the composition of the radioac-
tive metal. He thought that, since the Mo
was irradiated with deuterons, the missing
element 43 might be present. Together with
an analytical chemist, Carlo Perrier, at the
University of Palermo, Palermo, Italy, he
discovered the element technetium working
by analogy using chemical reactions that were
known for rhenium (5). Shortly, thereafter
Segre and Glenn Seaborg discovered Tc-99
and Tc-99m (6).
A dramatic change for nuclear medicine
occurred in the early 1950s at Brookhaven
National Laboratory (BNL), Upton, New
York, which brought the recently discovered
element into medical practice. The laboratory
was involved in the chromatographic separa-
tion of fission products and their possible
applications for the peaceful use of the atom.
The radioisotopes of iodine had been used in
medicine for some time so they were the first
focus of the laboratory research. In the process
of separating the daughter radiation, I-132,
from the fission product Te-132, the I-132 was
found to be contaminated with Tc-99m. This
observation and subsequent experiments led to
the development of the Mo-99/Tc-99m gen-
erator (7). When the long-lived parent Mo-99
(t1/2  66 h) was adsorbed to alumina, the
hort-lived daughter Tc-99m (t1/2 6 h) could
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365be eluted with isotonic saline (8). Of the conve-
niently available radionuclides, including the often-
used I-131, Jim Richards thought that technetium
had by far the best nuclear properties for imaging
with the Anger camera because the 140-keV
gamma emission had satisfactory tissue penetration
(50% is absorbed in 4.6 cm of tissue), yet the energy
was low enough to be collimated easily. In this case,
the imaging device was already in place and to-
gether they produced quality external imaging of
the biodistribution in vivo.
During the mid-1960s, I was in graduate school
studying the reaction of hot (energetic) silicon with
organic molecules, an early example of molecular
targeting that some thought was in anticipation of a
silicon-based life form. After a short stay at
Mallinckrodt Nuclear the successor to Wil Kon-
neker’s Nuclear Consultants, Inc., working on the
challenges of low-yield generators, I left for BNL.
At BNL, Jim Richards and I often discussed ex-
panding the use of Tc-99m; it was clear that a
further advance in the chemistry would be necessary
before Tc-99m was used widely. The chemical form
of Tc-99m eluted from the generator is pertechne-
tate (TcO4
), the most stable chemical state of
technetium in aqueous solution (9). But pertechne-
tate could not be used directly because it does not
Figure 1. The Original Mo-99/Tc-99m Generator (Shown
Without Lead Shielding)
The parent molybdenum-99 (Mo-99) is adsorbed to a small
amount of alumina. Pertechnetate is not adsorbed to the alu-
mina and can be eluted with a small volume of saline. This
provides a ready source of the 6-h half-life technetium-99m
(Tc-99m) in the clinic. Reprinted with permission from Richards (7).bind to chelating agents or directly to biologicalmolecules. Consequently, a less stable lower oxida-
tion state of Tc-99m must be formed using reduc-
ing agents. In the reduced state, technetium binds
readily to chelating agents, thereby forming such
compounds as Tc-99m diethylenetriaminepenta-
acetic acid (DTPA), Tc-99m human serum albu-
min, and Tc-99m–labeled red blood cells, which
turned out to be our early targets and the subject of
a patent.
What reducing agent was used for the first
studies? Many radiopharmaceuticals were formed
using ferric chloride and ascorbic acid as the reduc-
ing agent (10). Although this produced a suitable
radiopharmaceutical, the need to use special equip-
ment, such as a pH meter, and to prepare sterile
buffers prevented the routine use of Tc-99m radio-
pharmaceuticals in most nuclear medicine labora-
tories. No other “contrast media” used in radiology
required this much in-house preparation, and
therefore Tc-99m was destined to be an interesting
but little-used radionuclide. The introduction of
stannous ion as a reducing agent permitted pertech-
netate to be added to a vial containing the targeting
agent with no further pH adjustment or addition of
other chemicals. The reaction was deceivingly sim-
ple; pertechnetate is added to a vial, reduced at pH
4 to 7, and then bound by the chelating agent (11).
On a practical level, the use of stannous ion was a
key development and current radiopharmaceutical
Figure 2. The “Instant” Kit Formulation
Pertechnetate, eluted from the generator, is added to a vial con-
taining a reducing agent (stannous ion) and a targeting agent
(such as diethylenetriaminepentaacetic acid) formulated such
that upon the addition of pertechnetate, the Tc is reduced and
bound to the diethylenetriaminepentaacetic acid in high yield.
Although the procedure is deceivingly straightforward, Tc must
be reduced and bound to the chelating agent with 5% radio-
chemical impurities such as pertechnetate and reduced
colloidal Tc.
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366kits employ the stannous reduction technique. With
the advent of the Mo-99/Tc-99m generator in the
1960s (11) followed by the development of “instant”
kits (12), the use of Tc-99m–labeled compounds
expanded rapidly.
Because a stable or long-lived isotope of Tc
(Tc-99) was not available until much later, the
characterization of the structure and oxidation state
of these early radiotracers was carried out using
approaches similar to those Segre and Perrier used
to first identify the element. In collaborations with
Joseph Steigman and Jim Richards, we carried out
experiments to determine the oxidation state and
chemical form by observing the similarities with
well-known Re chemistry (13).
With the availability of long-lived Tc-99 (there is
no stable isotope of Tc) crystal structures were
elucidated for Tc radiopharmaceuticals. The publi-
cation of the first Tc crystal structures of potential
radiopharmaceuticals appeared simultaneously in
1978. In one, pertechnetate was reported to have
reacted with an impurity in thioglycolic acid to
produce oxotechnetium bis (thiomercaptoacetate)
anion (14). In the other seminal effort in inorganic
chemistry, pertechnetate was reduced by sodium
borohydride in ethanol in the presence of 1,2- or
1,3-dithiols, and the products were isolated as the
Tc bis structures (15).
After a stay at BNL, I moved to George Wash-
ington University (GWU), Washington, DC, to
join Dick Reba, where 2 choices we made for
targeted molecules illustrate the challenge with
Tc-99m. We choose to radiolabel quinuclidinyl
benzilate (QNB), a muscarinic antagonist with
I-123 because of QNB’s relatively low molecular
weight. We also radiolabeled palmitic acid with
Tc-99m. 4-[I-123]IQNB became the first ligand to
map mAChR in a human using external imaging
(16). On the other hand, Tc-99m palmitic acid did
not retain its biological activity. Although satisfac-
tory heart-to-blood ratios and expected metabolic
profiles have been observed over the past 30 years
for various Tc-99m fatty acids, the radiolabeled
fatty acids have not been shown to follow the
biochemical pathway of palmitic acid (17). This
illustrates the difficulty of incorporating not only
Tc-99m but its required chelating agent as well into
relatively small molecules. A limited number of
small molecules with a molecular weight of 500
Da have been radiolabeled and found to retain their
biological activity, namely Tc-99m TRODAT for
monitoring dopamine transporter densities (18)
and a Tc-99m lisinopril analog that monitors yangiotensin-converting enzyme densities (19).
But it is a challenge, considering the number of
successful I-123 small molecules that have re-
tained an important aspect of the biological
activity of the parent compound.
The development of Tc-99m myocardial perfu-
sion agents has an interesting history. In the heart,
201TI as the thallous cation was most often used as
a potassium surrogate to measure myocardial per-
fusion. The original goal was to produce a Tc-99m
radiotracer with a positive charge that would follow
the biochemical pathway of the thallous cation.
Although 99mTc cations, such as hexakis (2-
ethoxy-2-methylpropyl) isonitrile (sestamibi) (20)
nd 1,2-bis[bis(2-ethoxyethyl) phosphino] ethane
tetrofosmin) (21) were taken up in the myocar-
ium, the mechanism of action was not related to
otassium or thallium biochemistry. Yet their ex-
raction fraction was such that they were useful
adiopharmaceuticals for measuring myocardial
erfusion.
After my stay at GWU and a brief foray into
ositron emission tomography (PET) at the Na-
ional Institutes of Health, Bethesda, Maryland, I
oved to the Squibb Institute for Medical Re-
earch, New Brunswick, New Jersey, as the Vice
resident for Diagnostics. During that time, we
rought another myocardial perfusion agent to
he clinic, namely Tc-99m–labeled teboroxime, a
eutral compound that is taken up rapidly in the
eart and released rapidly from the heart (22).
e proposed teboroxime as a single photon
nalog of the PET radionuclide Rb-82, which
as a half-life of 1.25 min. The former has a short
iological half-life and the latter has a short
hysical half-life. At the time, myocardial perfu-
ion studies were being carried out using Rb-82
nd PET cameras that encircled the patient.
lthough the extraction approached 100% for
eboroxime and is unequaled in that aspect
mong radiopharmaceuticals, the net efflux from
he myocardium degrades the linearity of the
elationship of uptake with flow. Just as the
nger camera was not ideal for I-131, the rotat-
ng single-photon emission computed tomo-
raphs (SPECT) of the day were not fast enough
o measure perfusion with teboroxime in a matter
f minutes to take full advantage of the high
xtraction. Some 20 years later, SPECT is now
pproaching that capability. The necessary inter-
lay between the imaging device and the radio-
harmaceutical has been a constant over the
ears.
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367What is the future of Tc-99m? The strength of
nuclear medicine is the tracer principle (1) and,
when combined with the targeting of low-density
sites using the “magic bullet” concept of Ehrlich
(23), confers a unique quality to radiopharmaceuti-
cals. Tc-99m is best as a radiolabel for peptides
given that the Tc-99m chelate does not affect the
biological activity if placed appropriately in the
peptide and the pharmacokinetics of peptides best
match the physical half-life of Tc-99m (24). The
peptides studied to date are many: somatostatin,
VIP/PACAP, bombesin, CCK-B/gastrin, neuro-
tensin, alpha-MSH, neuropeptide Y, GnRH/
LHRH, substance P, and opioids (25). These
Tc-99m–targeted radiotracers are used for monitor-
ing the change in target density as a function of
disease progression or treatment. They also have
been employed in the burgeoning field of biomar-
kers for pharmaceuticals (26). Certainly, the rapid
growth of Tc-99m in nuclear medicine after the
discovery of the element in the late 1930s is
unparalleled. With the generator in the late 1950s
and instant kits in the late 1960s, a medical disci-
pline was established with the staying power to be a
major diagnostic technique over the past 5 decades.
Likewise, what is the future of the generator?
Do we need the generator, especially in these
times of unreliable sources of Mo-99 from a
limited number of aging reactors around the
world and the low probability that new reactors
will be built (27)? Will accelerator production of
Mo-99 via photo-fission using an electron accel-
erator (28) or via a cyclotron-based spallationXLVII–LII. and Nuclear Medica Pb-Bi target (ADONIS) (29) replace reactor
production of Mo-99?
Or should the direct production of Tc-99m on
an accelerator using Mo targets (30,31) replace
reactor production of Mo-99? Since the develop-
ment of the Tc-99m generator in the 1950s,
radiopharmacies have increased and shipment of
the shorter half-life F-18 in final chemical form
has become routine so perhaps a direct shipment
of either pertechnetate or the final Tc-99m ra-
diopharmaceutical should be the paradigm. It is
unlikely that Tc-94m will supply a PET answer
to the use of Tc because of the short half-life and
radionuclidic impurities (32). Or as the field of
targeted imaging moves to smaller molecules is
the use of I-123 going to expand? These are
questions that many scientific organizations are
addressing in terms of capital investments, cross
sections, production costs, waste disposal, and
distribution requirements. Few products have
avoided cannibalization in this era of discontinu-
ity (33). The Tc-99m generator has been rein-
vented on several occasions to address the need
for high specific activity Mo-99, for maintenance
of oxidized Tc in the form of pertechnetate in the
presence of generators that continue to increase
in total radioactivity, and for yet smaller alumina
columns and therefore less shielding. Will it
continue to stand the test of time as few products
have in the history of business?
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